Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. All clinical decisions are made by independent licensed clinicians based on individual patient evaluation. Consult a qualified healthcare provider before starting any therapy. New Blue Health is a technology and administrative services platform — not a medical provider.

NAD+ Therapy for Adults: What It Is, How Delivery Methods Differ, and What Research Shows

Most adults searching for information on NAD+ therapy encounter a confusing mix of anti-aging hype, oversimplified science, and vendor pages that blur the line between evidence and marketing. The molecule itself — nicotinamide adenine dinucleotide — is real, well-studied, and genuinely central to cellular metabolism. But separating what researchers have actually demonstrated from what the wellness industry wishes were true requires care. This article draws on published research and the clinical framework used by independent licensed clinicians who review patients through New Blue Health, a LegitScript-certified telehealth platform with over 14 years of experience in regulated health product supply chains.

What Is NAD+ and Why Does It Matter for Adults Over 35?

NAD+ is a coenzyme present in every living cell, essential for converting nutrients into usable energy (ATP) and serving as a substrate for enzymes involved in DNA repair, gene expression, and calcium signaling. Without adequate NAD+, mitochondrial function deteriorates — and mitochondria are, quite literally, where cellular energy production happens.

Why does age 35 matter? Because that's roughly when measurable decline begins to accelerate. NAD+ isn't a vitamin or a supplement in the traditional sense; it's a metabolic intermediate that participates in hundreds of enzymatic reactions. The enzymes that consume NAD+ — sirtuins, PARPs, and CD38 — become more active or more abundant with age, chronic inflammation, and metabolic stress. The result is a supply-demand mismatch: your cells need more NAD+ precisely when your body produces less of it.

For adults in their late 30s, 40s, and beyond, this decline correlates with observable changes: slower recovery from physical exertion, reduced cognitive sharpness, disrupted sleep architecture, and diminished cellular stress resilience. None of this means NAD+ therapy supports a reversal of aging. It means the molecule is a legitimate target of scientific inquiry, and understanding it matters if you're evaluating whether therapy might be relevant to your situation.

How NAD+ Levels Change With Age

NAD+ levels can drop by as much as 50% between the ages of 40 and 60, according to research published by Camacho-Pereira et al. (2016) in Cell Metabolism. The primary driver appears to be increased expression of CD38, an enzyme that degrades NAD+ and rises with chronic, low-grade inflammation — sometimes called "inflammaging."

This isn't a gentle, linear slope. The decline tends to accelerate after midlife, and it's compounded by lifestyle factors: poor sleep, sedentary behavior, excessive alcohol consumption, and caloric excess all increase NAD+ consumption. Conversely, caloric restriction and regular exercise have been shown to modestly support NAD+ biosynthesis, though the magnitude of that effect varies widely between individuals.

A key point often missed in popular coverage: NAD+ decline isn't just about feeling tired. The downstream effects touch DNA integrity. Imai and Guarente (2014), writing in Trends in Cell Biology, described how NAD+-dependent sirtuins regulate chromatin structure and genomic stability. When NAD+ drops, sirtuin activity drops, and the cell's ability to repair damaged DNA weakens. That's a mechanistic link between NAD+ status and age-related cellular dysfunction — not a marketing claim, but a biochemical observation replicated across multiple labs.

NAD+ Therapy: How It Works

NAD+ therapy involves the direct administration of nicotinamide adenine dinucleotide to support cellular levels of the coenzyme. Unlike oral precursors such as NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside), which must be converted through enzymatic steps before becoming NAD+, direct NAD+ administration bypasses those conversion bottlenecks.

There are several delivery methods in clinical use: intravenous (IV) infusion, subcutaneous or intramuscular injection, and nasal spray. Each has distinct pharmacokinetic properties — how quickly the molecule reaches systemic circulation, how long it remains bioavailable, and how practical it is for repeated use.

Through platforms like New Blue Health, clinician-guided NAD+ pathways include injectable NAD+ ($249/30-day or $549/90-day supply) and NAD+ nasal spray ($299). All pathways include medication, supplies, and shipping, with a separate $75 consultation fee (non-refundable). Whether a prescription is written depends entirely on an independent licensed clinician's assessment of the individual patient — prescriptions are never guaranteed.

All compounded NAD+ formulations are prepared at state-licensed 503A compounding pharmacies. They are not the same as mass-manufactured pharmaceuticals, and their regulatory status differs accordingly (more on that in the FAQ below).

IV NAD+ vs. Injectable NAD+: Key Differences

The distinction between IV and injectable NAD+ matters more than most articles acknowledge. Here's a direct comparison:

IV infusions deliver NAD+ directly into the bloodstream at 100% bioavailability, but the practical barriers are significant. Sessions typically last two to four hours, can cause flushing, chest tightness, or nausea during infusion, and cost $500–$1,000 per session at many brick-and-mortar clinics. For adults with demanding schedules, the time commitment alone is often prohibitive.

Injectable NAD+ — administered subcutaneously — offers a more practical alternative. Absorption isn't instantaneous the way IV delivery is, but subcutaneous injection provides sustained release into systemic circulation. The tradeoff is slightly lower peak plasma levels in exchange for dramatically improved convenience and lower per-dose cost.

Nasal spray delivery represents a third option. Intranasal absorption bypasses first-pass metabolism and may offer faster onset than subcutaneous injection, though published pharmacokinetic data specific to intranasal NAD+ remains limited. For some patients, a clinician may determine that nasal delivery is the most appropriate route based on individual factors.

What the Research Shows: Current Evidence on NAD+ Therapy

Honest assessment of the evidence requires acknowledging what's strong, what's preliminary, and what's still unknown.

What's well-established: NAD+ is essential for mitochondrial function, DNA repair, and sirtuin activation. This is not controversial. Decades of biochemistry research support it. Rajman, Chwalek, and Sinclair (2018), in a comprehensive review published in Cell Metabolism, detailed the mechanistic pathways through which NAD+ decline contributes to age-related metabolic dysfunction.

What's promising but still early: Human clinical trials on NAD+ precursors (NMN and NR) have shown that oral supplementation can raise blood NAD+ levels. Yoshino et al. (2021) published results in Science demonstrating that NMN supplementation improved insulin sensitivity in prediabetic women. However, direct NAD+ administration studies in humans are fewer in number, and most published data comes from preclinical models or small pilot trials.

What remains uncertain: Optimal dosing, frequency, and delivery route for direct NAD+ therapy in humans have not been established through large-scale randomized controlled trials. Individual responses vary. No compounded NAD+ formulation has undergone the formal regulatory review process that commercially manufactured pharmaceuticals go through.

This is precisely why clinician oversight matters. A licensed clinician evaluating a patient for NAD+ therapy should consider medical history, current medications, metabolic status, and realistic expectations. For a deeper look at the evidence base, New Blue Health maintains a dedicated NAD+ evidence page reviewed according to their editorial policy.

NAD+ and Cellular Energy: What Adults Should Know

Cellular energy production depends on the NAD+/NADH ratio within mitochondria. NAD+ accepts electrons during glycolysis and the citric acid cycle; NADH donates them to the electron transport chain. When NAD+ levels fall, this entire cascade slows down. Cells produce less ATP. Tissues that demand the most energy — brain, heart, skeletal muscle — feel the effects first.

For adults over 35, this often manifests as subjective fatigue that doesn't resolve with more sleep. It's not the same as iron-deficiency anemia or hypothyroidism (both of which should be ruled out clinically). It's a subtler decline in mitochondrial output that accumulates over years.

One underappreciated detail: NAD+ also regulates circadian rhythm through SIRT1's interaction with CLOCK-BMAL1 transcription factors. Nakahata et al. (2009) demonstrated this connection in Cell. Adults who notice worsening sleep quality alongside daytime fatigue may be experiencing, at least in part, a downstream effect of NAD+ insufficiency on circadian gene regulation.

NAD+ vs. Glutathione: How They Compare

Both NAD+ and glutathione are endogenous molecules that decline with age, but they serve fundamentally different roles.

They're complementary, not interchangeable. NAD+ drives energy production; glutathione protects cells from the oxidative byproducts of that energy production. Some clinicians may determine that both are appropriate for a given patient, while others may recommend one based on the individual's clinical picture. Neither replaces the other.

Who May Be a Candidate for NAD+ Therapy

Candidacy for NAD+ therapy is determined by an independent licensed clinician, not by a website quiz or a self-assessment. That said, the clinical profiles most commonly evaluated include:

• Adults over 35 experiencing persistent fatigue not explained by other diagnoses
• Individuals with high metabolic demands (athletes, physically active adults) seeking recovery support
• Adults interested in cellular health and longevity as part of a broader health strategy
• Patients with a history of metabolic stress, poor sleep, or chronic inflammatory conditions

NAD+ therapy is not appropriate for everyone. Pregnant or nursing individuals, those with certain active malignancies, or patients on medications that may interact with NAD+ pathways should disclose their full medical history during clinical intake. The clinician — not the platform — makes the prescribing decision.

How Clinician-Guided NAD+ Pathways Work Through Telehealth

New Blue Health operates as a technology and administrative services platform connecting patients with independent licensed clinicians and state-licensed 503A compounding pharmacies. The process is straightforward: a patient selects a pathway, completes a medical intake form, and a licensed clinician reviews the submission. If the clinician determines that NAD+ therapy is appropriate, a prescription is issued and the compounding pharmacy ships medication, supplies, and instructions directly to the patient. The $75 consultation fee is always separate from medication pricing and is non-refundable regardless of outcome. Service is available in 48 states — not in Alabama or Mississippi.

What makes this model distinct from many telehealth competitors is the separation between platform and clinical decision-making. New Blue Health does not employ the clinicians, does not influence prescribing, and does not guarantee that any patient will receive a prescription. Andy Palenzuela, the founder, built the platform around a compliance-first architecture informed by 14+ years working in regulated health product supply chains — a background that tends to produce more caution, not less, around clinical claims.

Safety Considerations and What to Discuss With Your Clinician

Before starting any NAD+ pathway, discuss the following with your clinician:

• Current medications and supplements, especially those affecting liver metabolism or mitochondrial function
• Pre-existing conditions, particularly kidney disease, liver disease, or active cancers
• Realistic expectations — NAD+ therapy is not a guaranteed solution for any specific symptom
• Side effects — injection site reactions, flushing, mild nausea, and lightheadedness have been reported
• Monitoring — whether follow-up labs or check-ins are recommended based on your clinical profile

Compounded medications carry inherent variability compared to commercially manufactured drugs. All compounded NAD+ available through New Blue Health is prepared at state-licensed 503A pharmacies, but patients should understand the compounding disclosure and ask questions during their consultation.

Frequently Asked Questions

What is NAD+ therapy?

NAD+ therapy involves the administration of nicotinamide adenine dinucleotide, a coenzyme involved in cellular energy metabolism and DNA repair. NAD+ levels naturally decline with age, and therapy is designed to support cellular function. Eligibility depends on clinical review by an independent licensed clinician.

What is the difference between IV NAD+ and injectable NAD+?

IV NAD+ is administered intravenously, typically in a clinical setting over a longer session. Injectable NAD+ is administered subcutaneously or intramuscularly and may offer more convenience for at-home use. Both involve compounded formulations prepared at state-licensed 503A compounding pharmacies, and your clinician can help determine which delivery method may be appropriate.

What is the regulatory status of compounded NAD+ formulations?

Compounded NAD+ formulations are not subject to the same regulatory review process as commercially manufactured pharmaceuticals. They are prepared at state-licensed 503A compounding pharmacies. If appropriate, a licensed clinician may prescribe compounded NAD+ based on individual clinical review.

How much does NAD+ therapy cost through telehealth?

Through New Blue Health, NAD+ injectable is $249/30-day supply or $549/90-day supply. NAD+ nasal spray is $299. All pathways include medication, supplies, and shipping. A separate $75 consultation fee applies and is non-refundable.

Is NAD+ therapy available in my state?

NAD+ therapy pathways are available in 48 states, subject to pathway, pharmacy, and provider availability. Service is not available in Alabama or Mississippi. Contact the care coordination team for confirmation regarding your state.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. All clinical decisions are made by independent licensed clinicians based on individual patient evaluation. New Blue Health is a technology and administrative services platform — not a medical provider, clinic, or pharmacy. Compounded medications are prepared at state-licensed 503A compounding pharmacies and have not undergone the same regulatory review as commercially manufactured pharmaceuticals. Consult a qualified healthcare provider before beginning any therapy.

Written by Andy Palenzuela — founder of New Blue Health, with 14+ years in regulated health product supply chains. Clinical content reviewed in accordance with New Blue Health's clinical content team standards.